Platinum-resistant ovarian cancer kills roughly 70% of patients within two years of diagnosis, and no biomarker-selected oral therapy has ever reached full approval in this setting — which is exactly what makes Zentalis launching ASPENOVA with 420 planned enrollees so consequential right now. The trial opens not as a standalone bet but as the second rail of a deliberate dual-track structure: DENALI Phase 2 chasing accelerated approval by year-end 2026, ASPENOVA running simultaneously as the FDA-aligned confirmatory study required to convert that accelerated approval into a full label. That sequencing collapses what is typically a multi-year gap between early and confirmatory evidence into a near-parallel timeline.
The biomarker logic is the real clinical story here. Cyclin E1 overexpression drives replication stress and is mechanistically linked to platinum resistance — it forces cells to rely on WEE1-mediated checkpoint activity to survive that stress. Inhibit WEE1 with azenosertib, remove that buffer, and Cyclin E1-overexpressing cells accumulate lethal DNA damage faster than normal tissue does. The April 2026 DENALI Part 2a interim data showed a clearly differentiated response rate at 400 mg QD on a 5-days-on, 2-days-off schedule versus 300 mg, with comparable toxicity — and that dose now locks in across both trials. That kind of interim-driven dose confirmation feeding directly into a Phase 3 design, mid-enrollment, is unusual and reflects genuine regulatory coordination rather than retrospective alignment.
ASPENOVA’s comparator arm — investigator’s choice among paclitaxel, PLD, gemcitabine, or topotecan — is the honest standard of care in platinum-resistant disease, where response rates with chemotherapy sit around 10–15%. PFS as the primary endpoint is the right call for accelerated approval conversion; overall survival as a key secondary gives the trial long-term commercial teeth without making the confirmatory bar unachievable. The GOG, ENGOT, and APGOT collaboration means enrollment infrastructure is genuinely global, which matters for hitting 420 biomarker-selected patients without years of screening attrition.
The single number that will define this program’s trajectory is the ORR from DENALI Part 2b — expected in the year-end 2026 topline readout. That response rate, in roughly 100 Cyclin E1-positive patients on 400 mg QD 5:2, is what the FDA will evaluate for accelerated approval and what sets the efficacy floor ASPENOVA’s PFS analysis must credibly exceed to complete the conversion.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
